Navigation Links
Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy
Date:12/8/2009

DURHAM, N.C., Dec. 8 /PRNewswire/ -- Hemodynamic Therapeutics, Inc. (HTI), a portfolio company of Cato BioVentures, announces the successful completion of its initial Phase 2 clinical study of its lead compound ("HTI-101"), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension. The 12-week double-blind placebo controlled Phase 2 study investigated the effects of a novel low dose combination of amiloride HCl and spironolactone in obese adults with treatment-resistant hypertension and statistically met its primary endpoint. HTI was assisted in the successful execution of this trial by Cato Research Ltd., a global contract research and development organization ("CRO") that is affiliated with Cato BioVentures.

"HTI remained as virtual as possible during these challenging economic times and to do this we have strategically leveraged the clinical and regulatory expertise of Cato Research in reaching this important clinical milestone for the company," said Daniel Pharand, CEO of HTI.

Obese patients were enrolled in the study with all experiencing uncontrolled hypertension while taking 3 or more anti-hypertensive medications. After only one month of treatment with HTI101, there was a significant decrease in both systolic and diastolic blood pressure.

"We are pleased to see such a strong response of HTI-101 in this important patient population and feel that this could be a new tool for treating unabated hypertension," said Allen Cato, M.D., Ph.D., CEO of Cato Research Ltd.

HTI obtained the core technology through an exclusive patent a license agreement with the University of Alabama Research Foundation ("UABRF").

About Hemodynamic Therapeutics, Inc.

HTI was formed in 2004 as a majority-owned portfolio company of Cato BioVentures. Through its strategic development relationship with Cato BioVenture
'/>"/>

SOURCE Hemodynamic Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... JOLLA, Calif. , Oct. 22, 2014 ... RGLS ), a biopharmaceutical company leading the ... microRNAs, today announced that it has demonstrated ... an ongoing clinical study evaluating RG-101, a ... the treatment of hepatitis C virus infection ...
(Date:10/20/2014)... 2014  Indianapolis interventional medical device maker ... -based 3D visualization leader Synaptive Medical ... Annual Meeting that they have joined forces to ... collaboration is the first of its kind and ... outcomes. NICO,s BrainPath® interventional access technology and Synaptive,s ...
(Date:10/20/2014)... , Oct. 20, 2014   BioNano Genomics ... system: the ability to collect human data at 30X depth, ... single chip.  This new capability was established and demonstrated for ... Irys TM System and will be rolled ... months. BioNano will be showcasing this advancement at the ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
... WASHINGTON, Nov. 16, 2011 The proliferation of brand ... generics to more expensive brands, will increase costs by ... for employers, unions, and state employee plans, according to ... Pharmaceutical Care Management Association (PCMA).  The use of ...
... Nov. 16, 2011   The proliferation of brand drug ... to more expensive brands, will increase costs by $308 ... unions, and state employee plans, according to new research ... Management Association (PCMA).  The use of these promotions ...
Cached Medicine Technology:Brand Drug 'Copay Coupons' Undermine Generics, Raise Health Costs by $1 Billion in New Jersey 2Brand Drug 'Copay Coupons' Undermine Generics, Raise Health Costs by $308 Million in Arkansas 2
(Date:10/22/2014)... October 22, 2014 Medical ... company, is happy to announce that our co-founder ... Staffing Industry Analysts’ Staffing 100 for 2014. Anderson ... “100 most influential people in the staffing industry,” ... Solutions, the 13th-largest healthcare staffing company in the ...
(Date:10/22/2014)... October 22, 2014 Shriners Hospitals for ... will change the current location of Shriners Hospitals for ... Limestone across from the University of Kentucky Albert B. ... ambulatory care center, owned and operated by Shriners Hospitals ... needs of children and their families well into the ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Best Cheap ... in the world. The site has recently announced that ... hosting supplier for people from around the world. , ... in operation today and is providing various kinds of ... the company insists on offering excellent customer service and ...
(Date:10/22/2014)... October 22, 2014 Richard Carlson, Managing ... industry leader with over 25 years experience. Mr. ... in the areas related to EDI, B2B Commerce, RFID ... an Editorial Advisory Board member for Pharmaceutical Commerce Magazine ... Blue Fin Group is a management and technology consulting ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... to increased blood pressure, according to a new study. ... pressure for young adult women or for teenagers, according to ... or moderately, their risk of high blood pressure was cut ... in older adult men and women," said lead researcher Dr. ...
Breaking Medicine News(10 mins):Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4
... injuries accounted for 3.5 percent of high school ... first study to examine rare injuries and conditions ... eye injuries, dental injuries, neck and cervical injuries ... in high morbidity, costly surgeries and treatments or ...
... to President-elect Barack Obama, American Association of Homes and Services for ... ways that the Obama administration can make both short-term gains and ... vulnerable people. , , These ... Force: Create Jobs in Aging Services; , Construct ...
... glasses a day linked to atrial fibrillation, study finds ... woman can have up to two drinks a day without ... a new study finds. , A group including Dr. Christine ... mined the data of the large-scale Women,s Health study, looking ...
... USC Viterbi School of Engineering has led to significant ... California safety net hospitals, allowing "many more hours of ... the program, the work will be expanded to include ... School,s Epstein Department of Industrial and Systems Engineering began ...
... COSTA MESA, Calif., Dec. 2 TROY Group, ... on-demand printing,solutions, announces the first digital printer for ... bond paper. The TROY SecureRx,printer allows healthcare providers ... complying with the security regulations,established by the Center ...
... Treadmill Desks May Increase Production of Small Blood Vessels in the Brain ... ... recent years have shown that walking on a regular basis lowers an ... now uncovering the exact reasons why. A recent study conducted at the ...
Cached Medicine News:Health News:Light Drinking Poses No Heart Risk for Women 2Health News:Operations engineering for more efficient operating rooms 2Health News:Operations engineering for more efficient operating rooms 3Health News:TROY SecureRx Revolutionizes Prescription Printing 2Health News:TROY SecureRx Revolutionizes Prescription Printing 3Health News:TROY SecureRx Revolutionizes Prescription Printing 4Health News:Employees Have Yet Another Reason To Lose Their Office Chairs In Favor Of A Treadmill Desk: Their Brain 2Health News:Employees Have Yet Another Reason To Lose Their Office Chairs In Favor Of A Treadmill Desk: Their Brain 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: